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Abstract 
Aim: Infliximab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, has been 
reported to be effective in refractory uveoretinitis in Behçet’s disease. Because it has 
been used clinically for a short time, information on its adverse effects is limited. We 
report a patient who developed cystoid macular edema (CME) following infliximab use 
for uveoretinitis associated with Behçet’s disease.  
Case Report: A 27-year-old man had refractory uveoretinitis and neuro-Behçet’s disease, 
and intravenous infliximab was administered.  
Results: One day after infliximab infusion, the patient complained of a decrease in the 
vision in his left eye. The visual acuity had decreased from 1.2 to 0.5. Daily optical 
coherence tomographic evaluations showed a progressive worsening of the CME, and 
fluorescein angiography showed a typical staining with a cystic pattern. Two weeks later, 
the height of CME appeared to reach a maximum level and thereafter gradually resolved 
in spite of the continuation of infliximab administration. The visual acuity improved 
while the patient was treated with repeated subtenon injections of steroids in addition 
to continuation of infliximab and finally increased from 0.15 to 1.2.  
Conclusions: Although the mechanism of CME is not known, clinicians should be aware 
that infliximab therapy might cause a development and worsening of CME. Thus, it is 
crucial to rule out preexisting abnormalities in the macula prior to commencing 
infliximab infusion. 
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Introduction 
Infliximab, a monoclonal IgG1 chimeric antibody against soluble and membrane-
bound anti-tumor necrosis factor (TNF)-α, is widely used to treat rheumatoid arthritis 
and Crohn’s disease. Its use has been extended to refractory uveoretinitis in Behçet’s 
disease since 2007 in Japan. The clinical findings showed that infliximab decreased the 
number of ocular attacks, and the findings suggested that it has a beneficial effect on 
chronic cystoid macular edema (CME). We report an unusual case of a 27-year-old man 
who developed CME after receiving infliximab for Behçet’s disease. 
Case Report 
A 27-year-old man was referred to our clinic with recurrent uveitis, aphthous ulcers of the oral 
mucosa, and genital ulcers in September 2005. His best-corrected visual acuity (BCVA) was 1.0 OD and 
1.2 OS. We diagnosed the patient with Behçet’s disease and treated him with colchicines and steroid eye 
drops. A subtenon injection of triamcinolone acetonide was given after each ocular attack. However, the 
frequency of ocular attacks increased with an increase in the density of bilateral cataracts especially in 
the right eye. The right eye developed uveoretinitis and refractory CME, and the visual acuity 
progressively decreased. No macular lesion was found in the left eye, and the visual acuity remained at 
1.2. 
In October 2007, the patient was admitted to our hospital with headaches, vertigo, and diplopia, and 
was diagnosed with neuro-Behçet’s disease with a brain lesion. He was examined by a neurologist, and it 
was jointly decided to treat the refractory uveoretinitis and neuro-Behcet’s disease with infliximab. His 
BCVA was 0.08 OD and 1.2 OS one day before the infusion of infliximab. His right eye had moderate 
iritis, progressive cataracts, retinal vasculitis, macular edema, and optic disc pallor. His left eye had 
slight iritis and cataract, but showed no abnormality by ophthalmoscopy and optical coherence 
tomography (OCT; fig. 1). Fluorescein angiography (FA) showed retinal vasculitis in both eyes (fig. 2). 
One day after the infusion of infliximab, he complained of blurred vision in his left eye. The BCVA 
was reduced to 0.08 OD and 0.5 OS. Fundus scanning by OCT showed a CME in the left eye (fig. 1). On 
the next day, the BCVA in the left eye decreased to 0.15, and the CME detected by OCT progressively 
worsened (fig. 1). FA 4 days after the first infusion of infliximab showed an increase in the severity of 
the CME (fig. 2), but the visual acuity improved to 0.6 OS in spite of the exacerbation of the CME. Two 
weeks after the first infusion of infliximab, a second infusion of the drug was done with a daily subtenon 
injection of 2 mg of dexamethasone sodium phosphate in the left eye for 1 week to prevent the 
worsening of the CME. There was no worsening of the CME after the second infusion of infliximab. 
One month after the first infusion of infliximab, the left BCVA improved to 1.2, and with no additional 
treatment, the CME was gradually reduced and completely resolved 3 months later. The CME in the left 
eye has not recurred since then. The CME in the right eye did not respond to the multiple subtenon 
injections of triamcinolone acetonide, but it appeared to have improved 21 months after the initiation of 
infliximab therapy. 
Discussion 
Evidence has accumulated that infliximab can control refractory uveoretinitis in 
Behçet’s disease [1–3]. In addition, infliximab has been reported to have beneficial effects 
on CME associated with chronic uveitis in Behçet’s disease [4]. Our patient complained of 
visual disturbances, and OCT showed a development and worsening of a CME after the 
first administration of infliximab. The CME worsened in the OCT images, but the BCVA 
gradually improved although the treatment regime was not altered. Thus, we decided to 
continue the therapy with infliximab. We treated the patient with a daily subtenon 
injection of dexamethasone sodium phosphate for 1 week after the second administration 
of infliximab, and a worsening of the CME did not occur. The CME gradually improved  
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even with the continued use of infliximab. The occurrence of CME has not been reported 
as a side effect of infliximab. 
On the other hand, it has been suggested that infliximab might be immunogenic and 
probably retinotoxic [5, 6]. Giganti et al. [5] reported that intravitreal infliximab in 
patients with refractory diabetic macular edema or choroidal neovascularization 
secondary to age-related macular degeneration was not well tolerated. The adverse events 
included persistence of CME, worsened appearance on angiography, development of 
inflammation (vitritis or panuveitis), and decrease of electroretinographically-determined 
retinal function. They mentioned that the undiminished diffuse edema and downward 
trend in ERG values seen in their patients partly corresponded with the findings observed 
in experimental rabbit eyes following relative high-dose intravitreal infliximab injection 
[6]. It is assumed that the possible mechanism involved in the complication in our patient 
was induced immune response, which may aggravate the CME. This is an adverse event 
in a single case and cannot be regarded as a definite adverse effect of the drug for patients 
with ocular Behçet’s disease. However, given the reasonable association of infliximab with 
CME, it might be crucial to rule out preexisting abnormalities in the macula prior to 
commencing infliximab infusion. 
Acknowledgements 
Support of this study was provided by Research Grants on Sensory and 
Communicative Disorders from the Ministry of Health, Labour, and Welfare, Japan, and 
from the Ministry of Education, Culture, Sports, Science and Technology, Japan. 
 
 
 
 
  
Case Rep Ophthalmol 2010;1:14–19 
DOI: 10.1159/000315489 
Published online: June 11, 2010  © 2010 S. Karger AG, Basel 
ISSN 1663–2699 
www.karger.com/cop 
 
 
17
Fig. 1. Optical coherence tomographic images of the left eye before and after the infliximab injection. 
a No obvious abnormalities are seen in the left macula 1 day before the first infliximab infusion. Visual 
acuity was 1.2. b One day after the first infliximab infusion, the outer nuclear layer appears to be thicker 
at the macula suggesting the beginning of macular edema. Visual acuity was 0.5. c Two days after the 
first infliximab infusion, macular edema can be seen. Visual acuity was 0.1. d Four days after the first 
infliximab infusion, OCT image showing that the macular edema is worsened and cystoid spaces in the 
inner nuclear layer can also be seen. This image was obtained on the same day as the fundus 
photographs of figures 2c and d. Despite the OCT findings, visual acuity improved to 0.6. e Fourteen 
days after the first infliximab infusion, localized serous retinal detachment developed within the still 
remaining macular edema. Again, contrary to the OCT findings, visual acuity further improved to 0.7. 
f One month after the first infliximab infusion, the macular edema is resolved and visual acuity 
improved to 1.2. 
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Fig. 2. Fundus FA before and after infliximab infusion. Top: FA, performed 1 day before the first 
infusion of infliximab, showed diffuse dye leakage involving macula of the right eye (a) and slight 
macular leakage and retinal vasculitis in the left eye (b). Bottom: FA, performed 4 days after the first 
infusion of infliximab (taken on the same day as that in fig. 1d), shows still active diffuse dye leakage 
involving the macula in the right eye (c) and extensive dye pooling and staining with a cystic pattern in 
the macula in the left eye (d). 
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